Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 7/20 | 0.67 |
| ▸ | P4HA1 | P13674 | 3/20 | 0.61 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.61 |
| ▸ | LDHA | P00338 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GABRP | O00591 | 1/20 | 0.49 |
| ▸ | GABRD | O14764 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.49 |
| ▸ | GABRE | P78334 | 1/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7318727 | 0.85 | HPGDS (0.58) | HPGDSP4HA1P4HTMKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL30685194 | 0.84 | HPGDS (0.56) | HPGDSKDM4EKMT2AFYN | |
| SCHEMBL14974164 | 0.82 | HPGDS (1.00) | HPGDSKDM4EL3MBTL1 | |
| SCHEMBL7317667 | 0.81 | HPGDS (0.57) | HPGDSKDM4EKMT2AL3MBTL1 | |
| SCHEMBL5440277 | 0.78 | HPGDS (0.54) | HPGDSKDM4EKMT2A | |
| SCHEMBL44435 | 0.78 | HPGDS (0.64) | HPGDSKMT2A | |
| SCHEMBL38227 | 0.78 | HPGDS (1.00) | HPGDSKDM4EL3MBTL1 | |
| SCHEMBL29683317 | 0.78 | P4HTM (1.00) | P4HA1P4HTMLDHAGABRPGABRD | |
| SCHEMBL29397057 | 0.78 | P4HTM (1.00) | P4HA1P4HTMLDHAGABRPGABRD | |
| SCHEMBL68560 | 0.78 | P4HTM (1.00) | P4HA1P4HTMLDHAGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784400-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-1608617-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| US-7705025-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | FINLEY DON RICHARD | 2010-02-04 | — | — | US | disclosed |
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-7378447-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7326731-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1644320-B1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7265246-B2 | Indane derivates as muscarinic receptor agonists | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-15 | — | — | US | disclosed |
| EP-0805813-B1 | TRICYCLIC VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID CO (US) | 2002-05-15 | — | — | EP | disclosed |
| CN-1052725-C | Tricyclic vasopressin antagonists | AMERICAN CYANAMID CO (US) | 2000-05-24 | — | — | CN | disclosed |
| US-6051574-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-5883105-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0891357-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5780471-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1998-07-14 | — | — | US | disclosed |
| CN-1178532-A | Tricyclic vasopressin antagonists | AMERICAN CYANAMID CO (US) | 1998-04-08 | — | — | CN | disclosed |
| WO-1997036898-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1996022292-A1 | TRICYCLIC VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5521173-A | TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | HPGDS 1221/4885P4HA1 846/4885P4HTM 1036/4885 |
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | CHRM1, CHRM3, CHRM2 | HPGDS 2225/4885P4HA1 3159/4885P4HTM 2222/4885 |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | HRH3, HRH4, HCRTR1 | HPGDS 1002/4885P4HA1 953/4885P4HTM 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.